Human Angiopoietin-2 / ANGPT2 (275-496) Protein
- Known as:
- Human Angiopoietin-2 / ANGPT2 (275-496) Protein
- Catalog number:
- AN2-H5242
- Product Quantity:
- 500ug
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human Angiopoietin-2 / ANGPT2 (275-496) Protein
Related genes to: Human Angiopoietin-2 / ANGPT2 (275-496) Protein
- Gene:
- ANGPT2 NIH gene
- Name:
- angiopoietin 2
- Previous symbol:
- -
- Synonyms:
- Ang2
- Chromosome:
- 8p23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-07-22
- Date modifiied:
- 2016-10-05
Related products to: Human Angiopoietin-2 / ANGPT2 (275-496) Protein
Related articles to: Human Angiopoietin-2 / ANGPT2 (275-496) Protein
- Non-invasive assessment of oocyte quality remains a challenge in assisted reproductive technology (ART). Through their bidirectional communication with the gamete, cumulus cells (CCs) act as a functional mirror of oocyte competence; however, the specific angiogenic signature within this microenvironment is still poorly understood. In the present study, we performed RNA-seq on CCs from healthy oocyte donors and infertile patients, utilizing a multi-pipeline bioinformatic approach (STAR-Cufflinks, TopHat-HTSeq, and HISAT2-StringTie) to establish a high-confidence, exploratory transcriptomic profile. A set of 234 differentially expressed genes (DEGs) consistently identified across pipelines was obtained, with functional enrichment highlighting blood vessel morphogenesis and angiogenesis as primary drivers of transcriptomic divergence between groups. RT-qPCR validation in individual samples confirmed statistically significant differences for (upregulated) and (downregulated) in infertile patients, while other angiogenesis-related genes, including , and , showed consistent but non-significant expression trends, suggesting alterations in angiogenesis-related processes within the follicular microenvironment. These findings support the presence of coordinated angiogenesis-related alterations in cumulus cells and provide a basis for future studies exploring their potential relevance in oocyte competence and ART outcomes. - Source: PubMed
Publication date: 2026/04/11
Baratas AlejandroPérez-Quiroga VictoriaPlanello RosarioAquilino MónicaSerrano MagdalenaCasa Moisés de laFranco-Iriarte YosuRoy Rosa - Hypertrophic cardiomyopathy (HCM) is characterized by substantial heterogeneity in both clinical phenotype and risk of adverse outcomes, including heart failure and sudden cardiac death. This highlights the need for robust biomarkers for risk stratification, and while previous studies have identified the role of select plasma proteins, comprehensive large-scale proteomic analyses have been limited in HCM. - Source: PubMed
Publication date: 2026/04/22
Chan Jonathan HGrace ChristopherMazidi MohsenClarke RobertHo Carolyn YNeubauer StefanKramer Christopher MWatkins HughGoel Anuj - The development of resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors and a poor response to immune checkpoint inhibitors (ICIs) remain challenges in ALK-rearranged non-small cell lung cancer (NSCLC). We performed immune-related gene expression profiling (irGEP) for ALK-rearranged NSCLC to assess the characteristics of the tumor microenvironment and explore potential therapeutic avenues. - Source: PubMed
Publication date: 2026/04/19
Kurosaki TakashiSuzuki ShinichiroWatanabe YasutakaKenmotsu HirotsuguItoh ShoichiYamaguchi MasafumiShiono AyakoSuzuki TakujiYokoyama ToshihideToi YukihiroTanaka HisashiOki MasahideTsuda TakeshiIchihara EikiAzuma KoichiTanaka HiroshiArai RyoUchibori KenMiyauchi EisakuKatayama RyoheiHayashi Hidetoshi - Abnormal tumor vasculature is a hallmark of breast cancer, characterized by tortuous, hyperpermeable, and poorly perfused vessels that contribute to hypoxia, therapeutic resistance, and immune exclusion. Vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG2) are central drivers of these vascular abnormalities, with VEGF promoting endothelial proliferation and leakiness, and ANG2 destabilizing vessel structure by antagonizing Tie2-mediated pericyte coverage. Monotherapies targeting VEGF provide only transient vascular normalization, as compensatory ANG2 upregulation limits efficacy. Dual inhibition of VEGF and ANG2 via bispecific antibodies offers a mechanistically grounded strategy to achieve more durable vascular normalization. Preclinical studies demonstrate that VEGF/ANG2 bispecific antibodies enhance pericyte coverage, reduce leakage, improve perfusion, alleviate hypoxia, increase intratumoral drug delivery, and promote immune cell infiltration, thereby suppressing tumor growth and metastasis. Early clinical trials indicate acceptable safety profiles and biologic activity, with greatest therapeutic potential observed in combination with chemotherapy, immune checkpoint inhibitors, and radiotherapy. Ongoing translational studies are focused on optimizing dosing, identifying predictive biomarkers, and overcoming resistance mechanisms. This review summarizes the biology of VEGF and ANG2 signaling, mechanisms of vascular normalization, preclinical and clinical evidence of VEGF/ANG2 bispecific antibodies, and current and future therapeutic applications in breast cancer, highlighting their potential to enhance multimodal treatment efficacy and improve patient outcomes. - Source: PubMed
Li MengHan FengjuanLing ShuangSu XiaoyueZhao YuxinLv ShaowaZhang Xiwu - Microvascular invasion (MVI) is a critical determinant of early recurrence and poor prognosis in hepatocellular carcinoma (HCC). The cellular and molecular mechanisms driving MVI, particularly the role of endothelial heterogeneity, remain incompletely understood. - Source: PubMed
Publication date: 2026/04/01
Zhang XinglongFu HuarongLu Jun